HAE Haemonetics Corporation

XNYS 120.22 Delayed
Find condors

Stock quote, options chain, IV rank, technicals, AI analysis, and institutional ownership. Iron condor setups Expected move IV rank history Fibonacci levels Insider trading

Market data may be delayed, incomplete, or inaccurate. Not a recommendation to buy, sell, or hold any security. Verify quotes with your broker before trading. See Terms §17.

HAE $120.22 —
Key stats
$120.22
52-Week Range
$51.00 – $132.00
YTD
+50.31%
IV Rank (30D)
2.72
Straddle Price
$10.25
P/C Vol Ratio
0.60
Market Cap
$5.5B
Open
$121.16
Day Range
$117.48 – $122.97
Volume
485,165
Prev Close
$119.93
Fair Value
MODEL: SHORT

A blended fair-value estimate combining up to six valuation methods. Each method is weighted by how well it fits the company — DCF down-weights for unprofitable names; DDM only fires for steady dividend payers; comparables down-weight when peer multiples disagree.

  • DCF (quality-aware) — projects free cash flow with a horizon that scales to business quality. True compounders (quality 6/6) get 10 years explicit + 10 years fade before terminal; cyclical/struggling names (quality 0-1) get a 5-year terminal cliff. Quality is scored from ROE, gross margin, growth, FCF margin, debt load, and FCF consistency — the same factors that drive market premium for compounders.
  • Market-Implied Growth (in Model Inputs) — reverse-DCF that answers "what growth rate is the market pricing in?". Lets you sanity-check the deviation: if implied growth is plausible for the business, the model's bearish flag may be wrong; if implausible, the market may be over-extrapolating.
  • DDM (Gordon Growth Dividend Model) — values the stream of future dividends. Only used when trailing yield ≥ 2% and dividend payments are stable — below that the dividend is a token payout and Gordon (which values only the dividend stream) systematically underprices growth names, so those route to DCF + comparables + market anchor instead.
  • P/E, EV/EBITDA, P/B, P/S — applies the peer-group median multiple to this company's per-share metric. Peers come from the same set as the "Related symbols" card. Earnings/sales metrics are forward-tilted by the company's recent revenue growth (capped at 25%) so they're comparable to peers' growth-embedded multiples — mimics how analysts use NTM rather than TTM. Per-multiple weights are biased by company quality (e.g. P/B down-weighted for asset-light tech).
  • Market Anchor (SMA50) — the 50-day moving average, weighted by recent trading-range stability (tighter Bollinger bands → higher weight). Captures information fundamentals miss (forward consensus, sentiment, supply/demand) — but only when recent trading is steady enough that the market has converged on a view. During wild breakouts or breakdowns the anchor's weight collapses.
  • Options Expected (B-L 30d) — the risk-neutral expected stock price at 30-day options expiration, derived from the full implied-volatility surface via Breeden-Litzenberger (second derivative of call price wrt strike → implied PDF, then E[S_T]). Forward-looking, captures all options-implied information (smile, skew, term structure) in one number. Weighted by chain liquidity. SP500-only at present (pre-computed daily). Backtest evidence: adds modest alpha across most bucket × holding combos.
  • Blended value — weighted average. Confidence reflects how many methods fired and how tight peer dispersion is.
  • Deviation pill — green when blended FV ≥ 10% above current price (undervalued); red when ≥ 10% below; grey otherwise.
10-yr Treasury (rf)4.90%
Beta vs SPY0.76
Cost of Equity (CAPM)8.69% (VRP-adj)
WACC8.11%
Volatility Risk Premium+1.0pp (IV − HV30)
Effective Tax Rate24.0%
Rev. Growth (YoY, DCF input)+7.8%
DCF Horizon10 years explicit + fade
Forward Tilt (NTM/TTM)×1.08 (applied to P/E, EV/EBITDA, P/S)
Free Cash Flow (TTM)$0.2B
Return on Equity (TTM)11.5%
Book / Price14.0%
Gross Margin (TTM)59.0%
FCF Margin (TTM)18.4%
Debt / Equity1.53
Quality Score3/6 — normal (10y DCF)
Market-Implied Growth+9.1% (reverse-DCF on current price)
SMA 50$111.47 (Market Anchor value)
SMA 20 / Bollinger Mid$120.10
Bollinger Width / SMA208.1% (drives anchor stability)
Net Debt$1.0B
Market Cap$6B
Peers used for multiples: ENOV, GEHC, GKOS, MMSI, NEOG, NVST, PODD, UFPT
60-Day Conviction
36%
20-Day Fair Value
≈ by Dec 8, 2026
$120.07
α -0.2% rank 24%
conviction
17%
40-Day Fair Value
≈ by Jan 6, 2027
$118.80
α -1.3% rank 24%
conviction
46%
60-Day Fair Value
≈ by Feb 4, 2027
$118.80
α -1.3% rank 24%
conviction
36%
MethodImplied PriceWeightDetail
DCF $109.40 20%
DDM (Gordon) n/a 0%
Peer P/E $70.96 6% median 32.1× · 5 peers
Peer EV/EBITDA $111.60 6% median 16.4× · 7 peers
Peer P/B $53.31 6% median 3.2× · 8 peers
Peer P/S $94.26 6% median 3.1× · 8 peers
Market Anchor (SMA50) $111.47 40% stability 100% (BB-width)
Options Expected (B-L 30d) $119.77 15% 15 strikes · skew +0.20
As of 2026-11-09 · updated
About
Industry (SIC)
SURGICAL & MEDICAL INSTRUMENTS & APPARATUS (3841) · industry map
Exchange
XNYS
Market Cap
$5.5B
Employees
3,009
List Date
1991-05-09
CIK
0000313143
Last Earnings
Nov 5 before open · −2.6% vs ±11.5% expected
Next Earnings
~Feb 4, 2027 (estimated)
Headquarters
Boston, MA
Homepage
https://www.haemonetics.com

Haemonetics Corp aims to improve patient care and reduce the cost of healthcare by providing medical products and solutions in the blood and plasma component collection, surgical suite, and hospital transfusion service spaces. As such, the company operates under three segments: plasma, blood center, and hospital. The Plasma segment includes end-to-end collection technologies, automated plasmapheresis systems (such as the NexSys PCS device), and donor management software designed for commercial plasma collectors. Hospital segment includes Blood Management Technologies (hemostasis analyzers, cel…

Summary
—
composite
—
No summary data available for this symbol yet.

Each spoke is this symbol's rank within its sector (0–100; the dotted ring marks the sector median at 50). Higher is more constructive for a long. One spoke — News sentiment — is an absolute reading, not a sector rank. Grayed spokes have no data. A fuller shape is a summary, not a recommendation.

Chart
Seasonality
'21'22'23'24'25'26Avg
Jan-4.01%-11.61%9.61%-10.19%-11.93%-16.65%-7.46%
Feb10.00%18.19%-7.77%-6.44%-0.98%-3.74%1.54%
Mar-14.21%9.91%7.16%15.09%-2.35%-11.77%0.64%
Apr-39.97%-20.64%1.11%8.44%0.00%6.85%-7.37%
May-13.95%24.45%2.14%-8.74%7.49%14.43%4.30%
Jun16.87%4.64%-1.65%-2.67%8.46%11.57%6.20%
Jul-10.25%3.22%9.97%8.85%-2.99%12.73%3.59%
Aug2.35%8.98%-2.74%-16.14%-27.06%18.76%-2.64%
Sep10.61%-0.52%-0.73%7.07%-8.97%3.29%1.79%
Oct-4.57%11.98%-3.32%-9.92%2.46%14.64%1.88%
Nov-27.59%1.61%-6.39%22.37%61.83%-0.30%*8.59%
Dec5.74%-7.34%1.48%-10.75%-1.00%---2.37%
Total-59.40%40.00%7.30%-10.44%4.97%52.63%5.84%
Technical Indicators

Quick-reference for reading the values below. Indicators combine to confirm a view — no single one is a trade signal on its own.

Trend Indicators
  • SMA 20 / 50 / 200 — price above = uptrend, below = downtrend. SMA 50 crossing SMA 200 is the golden/death cross.
  • EMA 12 / 26 — faster-reacting averages; 12 above 26 is short-term bullish.
  • MACD — bullish when MACD > signal (green badge), bearish when below. Divergence from price often precedes reversals.
  • ADX (14) — trend strength regardless of direction. <20 range, 20–25 weak trend, 25–50 trend, >50 strong trend.
  • +DI / −DI — +DI > −DI favors bulls; the reverse favors bears. Read alongside ADX.
Momentum Oscillators
  • RSI (14) — <30 oversold, >70 overbought. 40–60 is neutral; trending names can stay extreme.
  • Stochastic %K / %D — <20 oversold, >80 overbought. %K crossing %D is an early momentum signal.
  • Williams %R — inverted scale: <−80 oversold, >−20 overbought.

Oscillators work best in range-bound markets; in strong trends they give premature reversal signals.

Volume & Volatility
  • Bollinger Bands — price at upper band = overbought, lower = oversold. Narrow bands (squeeze) often precede expansion.
  • OBV — cumulative volume; rising OBV confirms uptrend, falling OBV confirms downtrend. Divergence from price is a warning.
  • Vol SMA 20 / Vol ROC — today's volume vs. 20-day average. Positive ROC with price move = conviction.
  • ATR / True Range — average daily $ move; sizing and stop-loss reference.
  • HV 20 / 30 / 60 — realized (historical) volatility. Compare to IV on the options cards: IV > HV = rich premium.

Confluence matters: trend + momentum + volume agreeing carries far more weight than any single indicator. For how these feed the spread scanner score, see the algorithm docs →

Trend Indicators

SMA 20: $120.01
SMA 50: $111.80
SMA 200: $80.18
Current: $120.34
EMA 12: $120.57
EMA 26: $117.58
MACD: 2.9944 | Signal: -0.3550
BULLISH
ADX (14): 39.40
TREND
+DI: 26.16
−DI: 11.83

Momentum Oscillators

RSI (14): 56.19
NEUTRAL
Stoch %K: 36.16
Stoch %D: 54.16
Williams %R: -70.60

Volume & Volatility

BB Upper: $124.80
BB Lower: $115.22
NEUTRAL
OBV: -923,710
Vol SMA 20: 681,904
Vol ROC: -4.08%
ATR: $4.38
True Range: $5.49
HV 20: 30.2%
HV 30: 54.0%
HV 60: 50.4%

Data Summary

Data Points: 500
Last Updated:
Date Range: 2024-11-08T00:00:00 – 2026-11-06T00:00:00
AI Analysis
Written before HAE’s Nov 5 earnings report, so it doesn’t reflect the results.

HAEMONETICS CORPORATION (HAE) - COMPREHENSIVE STOCK ANALYSIS

Executive Summary

Overall Assessment: BULLISH | Confidence Level: 7.5/10

Haemonetics presents a compelling bullish setup driven by exceptionally strong technical momentum, positive sector tailwinds, and an unusual risk/reward profile. The stock has surged 149.3% over the past year and continues to exhibit powerful uptrend characteristics with strong institutional accumulation signals. However, elevated volatility (HV20: 60.7%) and an upcoming earnings date (2026-11-05) introduce meaningful execution risk.

Key Drivers:

  • Powerful uptrend with strong momentum across all timeframes
  • Exceptional trend strength (ADX: 35.30) indicating directional conviction
  • Favorable industry dynamics (apheresis market expanding to $4.41B by 2031)
  • Positive earnings trajectory positioning HAE as "Top Momentum Stock"
  • Unusual defensive characteristics (negative beta) providing downside cushion

Primary Risks:

  • Near-term overbought conditions in stochastic indicators (70-74 range)
  • Dramatic volume contraction (-86.85% volume rate of change) raising follow-through concerns
  • Earnings catalyst in 20 days could trigger profit-taking after 149% rally
  • Valuation stretched relative to historical ranges (price well above 200-day MA)

Investment Thesis: HAE exhibits textbook momentum characteristics with a strong uptrend (price above all moving averages), powerful directional trend strength (ADX: 35.30), and favorable sector catalysts supporting the rally. The unusual negative beta (-0.01) provides defensive characteristics uncommon in high-momentum equities, suggesting institutional quality underlying the move. However, deteriorating volume trends and overbought stochastic readings warrant caution on entry timing before the November 5th earnings announcement.

Recent News Sentiment Impact: POSITIVE The recent news flow strongly validates the technical rally, with headlines emphasizing HAE's 149% annual gain and momentum characteristics (Oct 16, Oct 13). The broader industry catalyst (apheresis market growth, July 24) provides fundamental support for the technical advance. Importantly, news sentiment aligns with technical signals—both are bullish—reducing the risk of a "contrarian" breakdown.

Technical Analysis

Trend Direction

| Timeframe | Status | Conviction | |-----------|--------|-----------| | Short-term (1-4 weeks) | STRONG UPTREND | Very High | | Medium-term (1-3 months) | STRONG UPTREND | Very High | | Long-term (3-12 months) | ESTABLISHED UPTREND | Very High |

Detailed Assessment:

Short-term (1-4 weeks): Price at $116.16 trades decisively above all key moving averages—SMA 20 ($112.70), SMA 50 ($107.52)—creating a clean uptrend structure. The EMA 12 ($116.38) sits nearly at current price, confirming very recent strength. The ADX reading of 35.30 is exceptionally strong (>25 indicates established trend), with +DI (26.48) far exceeding -DI (14.07), demonstrating powerful directional conviction. This is textbook uptrend confirmation.

Medium-term (1-3 months): The gap between price ($116.16) and SMA 50 ($107.52) is 8 points (+7.4%), and the uptrend has clearly established itself over weeks. The MACD histogram at +4.04 (and MACD at 3.91 above signal at -0.13) confirms sustained bullish momentum, though the divergence between MACD and signal line warrants monitoring for potential momentum deceleration.

Long-term (3-12 months): The most impressive metric is the price position relative to the 200-day SMA of $77.50—HAE trades 50% above this level. The annualized 149.3% gain confirms a powerful multi-month uptrend. This represents a structural shift in the stock's trajectory and suggests institutional accumulation behind the move.

Support/Resistance Levels

Resistance (in order of proximity):

  1. Upper Bollinger Band: $127.75 — Currently 9.9% above price. This represents the first technical ceiling. Historical pattern suggests mean reversion when bands widen significantly.
  2. $120-122 zone — Psychological and technical resistance. Previous earnings/news-driven rallies have peaked in this range.
  3. $130-135 zone — Pre-announcement resistance based on 149% annual rally structure.

Support (in order of proximity):

  1. SMA 20: $112.70 — Most important near-term support. A close below this would signal weakening short-term momentum.
  2. SMA 50: $107.52 — Critical medium-term support. Breach would confirm intermediate-term uptrend failure.
  3. 200-day SMA: $77.50 — Long-term support. Extremely unlikely given trend strength, but represents absolute foundational support.
  4. $110 psychological level — Round-number support historically significant.

Critical Observation: The wide Bollinger Band width ($26.71) and neutral BB signal indicates the stock is neither severely extended nor compressed—price sits within normal volatility parameters, though in the upper half of the bands.

Momentum Signals

RSI (14): 59.60 — NEUTRAL (Not Overbought)

  • Interpretation: At 59.60, RSI occupies the neutral zone (30-70 range). Critically, it is NOT overbought (>70), which would typically trigger sell signals. This suggests room for further upside without immediate technical exhaustion. This is a bullish signal often missed—the stock can continue higher without RSI becoming stretched.
  • Implication: Momentum is sustained but not extreme. Typical overbought readings in strong trends occur at 70-80 range; HAE is comfortably below this threshold.

MACD: 3.91 / Signal: -0.13 / Histogram: +4.04 — STRONG BULLISH

  • Interpretation: The MACD line (3.91) is well above the signal line (-0.13), creating a large positive histogram of +4.04. This is classic bullish momentum configuration.
  • Concern: The signal line at -0.13 (near zero) and positioned below MACD suggests the signal line is lagging. In mature trends, MACD can remain above signal for extended periods. However, watch for a MACD histogram contraction—this would be the first warning of momentum deceleration before a crossover.
  • Implication: Momentum is strong, but with ADX at 35.30 already indicating "maximum trend conviction," further MACD expansion may be limited. Any histogram compression toward zero should trigger caution.

Stochastic %K: 70.56 / %D: 73.69 — OVERBOUGHT WARNING

  • Interpretation: Both K (70.56) and D (73.69) are in overbought territory (>70). This is a near-term exhaustion signal that suggests short-term consolidation or pullback is likely. The K line touching 70 typically precedes corrective moves in 3-5 day periods.
  • Critical Nuance: Stochastic overbought in a strong uptrend (confirmed by ADX: 35.30, RSI: 59.60) often triggers short-term profit-taking but rarely reverses the primary trend. This suggests near-term pullback risk, not trend reversal.
  • Implication: Aggressive traders should reduce position size ahead of the earnings date. Conservative traders should wait for a stochastic reset below 50 before adding exposure.

Williams %R: -33.89 — NEUTRAL TO BULLISH

  • Interpretation: Williams %R between -50 and 0 indicates a stock trading in the upper portion of its recent range but not yet at extremes. At -33.89, the stock has room to run upward without hitting the maximum overbought level (-20 to 0).
  • Implication: Confirms that while stochastic is overbought, Williams %R suggests the stock retains upside potential if momentum persists.

Momentum Synthesis: The divergence between RSI (neutral 59.60), Stochastic (overbought 70+), and Williams %R (neutral -33.89) suggests near-term consolidation is likely, but the primary uptrend remains intact. The market may be pricing in earnings anticipation (due 11/5), causing

Generated
News
All HAE news →
IBDT2·12d ago
Blood Plasma Name Hits Highs On FDA Approval As Earnings Loom
Haemonetics provides tools for blood products management such as plasma collection and providing systems, training and services for blood collection. The post Blood Plasma Name Hits Highs On FDA Approval As Earnings Loom appeared first on Investor's Business Daily .
Earnings$HAE
Earnings History
16 of 24 under expected move
Avg Expected Move
10.89%
Avg Actual Move
8.69%
Each row pairs the pre-earnings straddle-implied expected move with the realized close-to-close move. Sorted oldest first.
Earnings Date Timing Expected Move Actual Move Ratio Outcome
2021-02-02 Pre-Market 12.78% 12.98% 1.02x Exceeded
2021-05-13 Pre-Market 14.21% 13.40% 0.94x Within
2021-08-11 Pre-Market 10.56% 7.29% 0.69x Within
2021-11-09 Pre-Market 11.74% 15.37% 1.31x Exceeded
2022-02-08 Pre-Market 10.86% 16.16% 1.49x Exceeded
2022-05-10 Pre-Market 12.34% 10.37% 0.84x Within
2022-08-10 Pre-Market 6.69% 8.89% 1.33x Exceeded
2022-11-07 Pre-Market 12.12% 3.61% 0.30x Within
2023-02-07 Pre-Market 5.70% 5.91% 1.04x Exceeded
2023-05-11 Pre-Market 10.95% 3.30% 0.30x Within
2023-08-08 Pre-Market 7.78% 1.46% 0.19x Within
2023-11-02 Pre-Market 9.26% 1.08% 0.12x Within
2024-02-08 Pre-Market 8.82% 1.30% 0.15x Within
2024-05-09 Pre-Market 8.72% 0.70% 0.08x Within
2024-08-08 Pre-Market 7.12% 10.84% 1.52x Exceeded
2024-11-07 Pre-Market 13.24% 10.71% 0.81x Within
2025-02-06 Pre-Market 11.76% 11.58% 0.98x Within
2025-05-08 Pre-Market 11.87% 5.85% 0.49x Within
2025-08-07 Pre-Market 8.94% 26.58% 2.97x Exceeded
2025-11-06 Pre-Market 16.07% 32.31% 2.01x Exceeded
2026-02-05 Pre-Market 13.04% 1.41% 0.11x Within
2026-05-07 Pre-Market 13.15% 3.23% 0.25x Within
2026-08-06 Pre-Market 12.17% 1.70% 0.14x Within
2026-11-05 Pre-Market 11.46% 2.60% 0.23x Within

Earnings calendar: this week’s reports with expected vs actual moves →

HAE Options Activity & IV Rank

HAE IV rank history, 52-week IV rank and IV percentile →

Volatility Metrics

Current IV: 33.0%
7-DTE IV: 35.2%
Expected Move: $10.25
7-DTE Move: $5.88
Days to Exp: 39 (2026-12-18)

Options Flow · All expiries

Call Volume: 513
Put Volume: 310
P/C Volume: 0.604
BULLISH
Call OI: 4,421
Put OI: 2,412
P/C OI: 0.546
Total OI: 6,833

ATM Options Pricing

ATM Call: $5.40
ATM Put: $4.85
Call %: 4.5%
Put %: 4.0%

Chain Summary

Chain Volume: 823
Chain OI: 6,833
Last Updated: 11/9/2026
Spread Scanner
Full Algorithm Docs ↗

Each spread is ranked by a composite score built in three stages. Full documentation →

Stage 1 — Base Score

score = P(profit) × (credit / spread_width)
P(profit) from short leg delta (1 − |delta|), penalised above 85%. Credit uses mid-price to handle illiquid chains fairly.
Calendars: the long leg is valued at the short leg’s expiration (Black-Scholes at its current IV) across the range of prices the short leg’s IV implies, giving the best-case profit (R/R = that over the debit) and P(profit).

Stage 2 — Skew Adjustment (±25% cap)

RR and BF (30-delta) from the persisted per-symbol skew snapshot — wing strikes picked by real greeks.delta, not a moneyness proxy. Put skew boosts bull puts, penalises bear calls. High butterfly boosts iron condors. Calendars are skew-neutral.

Stage 3 — Technical Overlay (±50% cap, 5 groups)
Group 1 · Directional Bias (±0.25)
  • RSI <40 bullish / >60 bearish
  • MACD crossover + histogram trend
  • Price vs SMA 50 & SMA 200
Group 2 · Momentum (±0.10)
  • Stochastic %K <20 / >80
  • Williams %R <−80 / >−20
Group 3 · Volatility (up to −0.25 / +0.15)
  • Blended ATR + straddle expected-move penalty
  • Bollinger Band signal (+ counter-trend penalty)
  • BB width — vol contraction boost for ICs
Group 4 · IV Regime (±0.15)
  • IV rank ≥ 75 → strong boost for credit spreads
  • IV rank < 25 → penalty (selling cheap vol)
Group 5 · Liquidity (penalty up to −0.10)
  • Min open interest across all legs
  • OI < 100 → −0.10 · OI < 500 → −0.05

score = base_score × skew_multiplier × tech_multiplier
Both multipliers are shown per spread. Beta is informational only — ATR already captures realized vol. Full algorithm documentation →

Scanning bull put, bear call, iron condor and calendar spreads…

Dealer Positioning
TYPICAL γ

Estimated net dealer gamma is at the 56th percentile of this name's own daily history, within its typical range. This describes current positioning; it is not a forecast or a trading signal.

Gamma percentile
56%
vs own history
GEX tilt
+0.11
OI-weighted, today
Vanna tilt
+0.46
δ-sensitivity to IV
Charm tilt
-0.61
δ-decay vs time
Vanna tilt +0.46: the estimated dealer exposure leans positive, so the modeled hedge would shift noticeably if implied volatility changed.
Charm tilt -0.61: the estimated dealer exposure leans negative, so the modeled hedge would shift noticeably as time passes and options approach expiry.

Net dealer gamma is an estimate of the aggregate gamma held by options market makers across this name's option chain, weighted by open interest. Dealer positions aren't public, so it uses a standard simplifying assumption: dealers are treated as long the calls and short the puts that are open. Actual dealer books can differ.

Gamma percentile ranks today's estimate against this name's own daily history, from 0% (the lowest reading on record) to 100% (the highest). Raw gamma scales with how much open interest a chain carries, so it isn't comparable across names; the percentile is. The badge marks the bottom 20% as low and the top 20% as high.

Tilts run from −1 to +1 and show how lopsided the estimated dealer exposure is. GEX tilt compares call gamma with put gamma. Vanna tilt describes how the hedge would shift if implied volatility changed, and charm tilt how it would shift with the passage of time.

This card describes estimated positioning and where it sits historically. It is not a forecast of price direction or volatility and not a trading signal. Market-wide view: Dealer positioning screener.

· 24 ATM contracts, 3k total OI
Skew (Wing IV − ATM IV)
DTE:
Wing Δ:
Metric:
Wing vs ATM
IV(put wing) − IV(ATM), in vol points

How much the OTM put trades above (or below) the at-the-money strike. Measures the height of the put-side tail relative to ATM — i.e. how expensive crash insurance is on this name.

  • Positive (typical) — wing IV > ATM IV. Standard equity put skew: portfolios bid up crash protection, so OTM puts trade richer than ATM.
  • Near zero or negative (unusual) — wing IV ≤ ATM IV. Flat or inverted put side. Common when there's no fear demand, in tightly mean-reverting names, or right after an earnings catalyst clears.
  • Percentile vs own 3-yr history: high = wings rich (good time to sell wing premium); low = wings cheap (good time to buy protection).
  • Not directional — high or low wings don't predict up or down moves. It's a price tag on tail insurance, not a forecast.
Risk Reversal
IV(call wing) − IV(put wing), equal delta on each side

Which side of the smile is the market paying up for? Measures the tilt of the surface — call skew vs put skew at matched deltas.

  • Negative (typical) — puts richer than calls. Standard equity behavior: hedging demand makes puts carry a premium. Most large-caps sit in the −1 to −5 vol-point range.
  • Strongly negative (< −5 pts) — heavy downside hedging, elevated fear, or an upcoming catalyst (earnings, FDA, macro event). Worth flagging.
  • Positive — calls richer than puts. Unusual for equities; signals bullish momentum, short-squeeze positioning, or takeover/M&A speculation.
  • Near zero — symmetric surface. Market sees roughly equal up/down risk. Rare for large-caps; more common in commodities and FX.
Reading them together

Wing-vs-ATM tells you how expensive the tails are. Risk Reversal tells you which side is favored. Combined:

  • High wing percentile + deeply negative RR → strong put bid; stress or major event priced in. Owning protection costs a premium; selling put premium is dangerous.
  • Low wing percentile + near-zero RR → complacency; insurance cheap and balanced. Good environment to add cheap downside hedges.
  • Positive RR + elevated wings → call-side fear-of-missing-out; common in squeeze setups. Upside calls expensive, downside puts not bid.
14 DTE / 10d —
— pts EXTREME
No data
30 DTE / 10d —
— pts EXTREME
No data

Percentile is the rank of today's reading within ~3 years of this symbol's own history. High percentile = wings are rich relative to history; not a directional signal. Skew is read off the chain in real time, not from CBOE SKEW.

Volatility Surface

Loading the implied volatility surface…

Volatility Smile

Loading the implied volatility smile…

IV Rank (7 DTE)2.2LowNov 9
IV Rank (30 DTE)2.7LowNov 9
Straddle Price (30 DTE)$10.25Nov 9
Beta Analysis

Risk Metrics

Beta: 0.2922
Alpha: 60.80%
Correlation: 0.0981
R-Squared: 1.0%
Stock Volatility: 41.0%
Market Volatility: 13.8%

Analysis Details

Benchmark: SPY
Data Points: 251
Period: 252 trading days
Interpretation:
Low volatility - stock moves less than market
Beta & Alpha Over Time
Notable investors who own HAE
7 of 37 tracked investors
InvestorValueShare of their portfolioRankQ/Q sharesSource
Citadel Hedge fund
Ken Griffin
$113.3M
0.07%
#366 of 6285+485.0%13F
Millennium Management Hedge fund
Izzy Englander
$58.5M
0.04%
#541 of 3716+164152.0%13F
Renaissance Technologies Hedge fund
Jim Simons
$9.8M
0.01%
#1068 of 3138+200.9%13F
Point72 Hedge fund
Steve Cohen
$8.2M
0.01%
#817 of 1945+92.1%13F
Bridgewater Associates Hedge fund
Ray Dalio
$4.5M
0.02%
#499 of 997+23.5%13F
Oaktree Capital Asset manager
Howard Marks
$2.1M
0.04%
#112 of 130+149.7%13F
Rockefeller Capital Management Family office
Rockefeller family
$39K
0.00%
#3471 of 4729-41.0%13F

Hedge funds, activists, holding companies and family offices we track, from their latest 13F (quarter-end value) and Form 4 filings in the last 3 years. Family offices · all institutions

HAE Institutional Ownership (13F)

Filings for 2026-06-30 · 142 already for 2026-09-30
Diluted shares outstanding: 47,589,500 (as of 2026-03-28)

Institutional managers with $100M+ AUM file Form 13F-HR quarterly, due 45 days after quarter end. Holdings are reported gross at quarter-end market value — they are a snapshot, not a real-time position.

  • Shares — long equity positions in this name, aggregated across share classes.
  • Calls / Puts — notional value of long call / put exposure where this ticker is the underlying.
  • % of Float — holder's reported shares divided by the latest diluted shares outstanding. Sums above 100% indicate large custodian / prime broker positions where the same shares are reported by multiple filers.
  • Custodian badge — filers with more than 5,000 holdings are typically broker-dealers / custodians reporting customer-held shares, not active managers.

Each filer is counted once at its latest 13F-HR filing. New filings are ingested on a weekly cadence.

381 filers749,442,318 shares$4.57B value1574.81% of float
# Filer Shares Value % of Total % of Float Period
1 BlackRock, Inc. Custodian 67,309,258 $505.26M 11.06% 141.44% 2026-06-30
2 Neuberger Berman Group LLC 4,179,443 $313.47M 6.86% 8.78% 2026-06-30
3 Vanguard Portfolio Management LLC 2,546,394 $190.98M 4.18% 5.35% 2026-06-30
4 Linden Advisors LP 176,911,000 $179.23M 3.92% 371.74% 2026-06-30
5 AQR Capital Management, LLC Custodian 2,266,489 $165.02M 3.61% 4.76% 2026-06-30
6 ARIEL INVESTMENTS, LLC 2,060,966 $154.57M 3.38% 4.33% 2026-06-30
7 State Street Corp 19,700,186 $154.49M 3.38% 41.40% 2026-06-30
8 Vanguard Capital Management LLC 2,059,578 $154.47M 3.38% 4.33% 2026-06-30
9 Dimensional Fund Advisors LP Custodian 1,279,678 $134.75M 2.95% 2.69% 2026-09-30
10 Geode Capital Management, LLC Custodian 1,245,890 $131.21M 2.87% 2.62% 2026-09-30
11 Citadel Advisors LLC Custodian 1,510,120 $113.26M 2.48% 3.17% 2026-06-30
12 River Road Asset Management, LLC 1,285,602 $96.42M 2.11% 2.70% 2026-06-30
13 Arrowstreet Capital, Limited Partnership 1,155,351 $86.65M 1.90% 2.43% 2026-06-30
14 T. Rowe Price Investment Management, Inc. 1,101,371 $82.60M 1.81% 2.31% 2026-06-30
15 Goldman Sachs Group Inc Custodian 1,046,019 $78.45M 1.72% 2.20% 2026-06-30
16 UBS Group AG Custodian 983,378 $73.75M 1.62% 2.07% 2026-06-30
17 Invesco Ltd. Custodian 59,369,019 $72.81M 1.59% 124.75% 2026-06-30
18 Deutsche Bank AG Custodian 1,586,905 $65.96M 1.44% 3.33% 2026-09-30
19 Franklin Resources, Inc. Custodian 36,347,479 $62.63M 1.37% 76.38% 2026-06-30
20 Royal Bank of Canada Custodian 780,248 $58.52M 1.28% 1.64% 2026-06-30
21 Millennium Management LLC Custodian 16,070,413 $58.49M 1.28% 33.77% 2026-06-30
22 Assenagon Asset Management S.A. 453,579 $47.76M 1.05% 0.95% 2026-09-30
23 T. Rowe Price Associates, Inc. 636,797 $47.76M 1.05% 1.34% 2026-06-30
24 FORT WASHINGTON INVESTMENT ADVISORS INC /OH/ 450,936 $47.48M 1.04% 0.95% 2026-09-30
25 Northern Trust Corp Custodian 631,542 $47.37M 1.04% 1.33% 2026-06-30
6 filers$26.56M notional
# Filer Notional Value % of Total Period
1 Millennium Management LLC Custodian $7.50M 28.24% 2026-06-30
2 Goldman Sachs Group Inc Custodian $6.75M 25.42% 2026-06-30
3 Susquehanna International Group, LLP Custodian $6.51M 24.51% 2026-06-30
4 Jane Street Group, LLC Custodian $3.68M 13.87% 2026-06-30
5 Citadel Advisors LLC Custodian $1.74M 6.55% 2026-06-30
6 CSS LLC/IL $375.00K 1.41% 2026-06-30
5 filers$8.78M notional
# Filer Notional Value % of Total Period
1 Goldman Sachs Group Inc Custodian $6.75M 76.88% 2026-06-30
2 Susquehanna International Group, LLP Custodian $1.10M 12.56% 2026-06-30
3 Citadel Advisors LLC Custodian $525.00K 5.98% 2026-06-30
4 Jane Street Group, LLC Custodian $360.00K 4.10% 2026-06-30
5 WOLVERINE ASSET MANAGEMENT LLC $42.12K 0.48% 2026-09-30

HAE Insider Trading (Form 4)

Latest: 2026-11-03
Form 4 filings — insider beneficial-ownership changes by officers, directors, and 10%+ holders. Filed within 2 business days of transaction.
Filed Reporter Role Action Shares Avg Price Net $ Link
2026-11-03 Roy Galvin EVP, Chief Commercial Officer Tax (F) −146 $119.65 -$17.5K EDGAR
2026-07-28 Ellen M Zane Director Award (A) +2,538 — EDGAR
2026-07-28 Lloyd Emerson Johnson Director Award (A) +2,538 — EDGAR
2026-07-28 Martin D Madaus Director Award (A) +2,538 — EDGAR
2026-07-28 Diane M Bryant Director Award (A) +2,538 — EDGAR
2026-07-28 Robert E Abernathy Director Award (A) +2,538 — EDGAR
2026-07-28 Michael J Coyle Director Award (A) +2,538 — EDGAR
2026-07-28 Mark W Kroll Director Award (A) +2,538 — EDGAR
2026-07-28 Claire Pomeroy Director Award (A) +2,538 — EDGAR
2026-06-08 Farris Maryanne Maunsell VP, Chief Accounting Officer Tax (F) −259 $71.28 -$18.5K EDGAR
2026-06-08 Laurie A. Miller SVP, Human Resources Tax (F) −313 $71.28 -$22.3K EDGAR
2026-05-19 Christopher Simon President & CEO Mixed
Grant +78,344 · Tax −9,681
 +68,663 $56.29 -$544.9K EDGAR
2026-05-19 Laurie A. Miller SVP, Human Resources Mixed
Grant +13,323 · Tax −948
 +12,375 $56.29 -$53.4K EDGAR
2026-05-19 Roy Galvin EVP, Chief Commercial Officer Mixed
Tax −879 · Grant +27,535
 +26,656 $56.29 -$49.5K EDGAR
2026-05-19 Farris Maryanne Maunsell VP, Chief Accounting Officer Mixed
Grant +2,220 · Tax −197
 +2,023 $56.29 -$11.1K EDGAR
Codes: P = open-market purchase · S = open-market sale · A = grant/award · M = option exercise · F = tax withholding at vest · G = bona-fide gift · D = disposition to issuer · J = other (described in filing footnote — typically 401(k), trust, inheritance) · W = will/inheritance. Only P / S codes carry directional signal.

HAE Insider Holdings

16 insiders · @ $120.34
Officers, directors, and 10%+ owners who have filed a Form 4 in the past two years, ranked by current disclosed exposure (shares × today's price). Shares are direct + indirect (via trusts / LLCs / spouse). Excludes unvested RSU and option grants — those aren't beneficially owned until vest.
# Insider Role Shares Disclosed Exposure Lifetime OM Net Filings Last Filed
1 Christopher Simon President & CEO 366,360 $44.09M -$20.14M 44 2026-05-19
2 Michelle L Basil EVP and General Counsel 68,829 $8.28M -$11.60M 41 2026-05-19
3 James DArecca EVP, Chief Financial Officer 54,444 $6.55M $0 13 2026-05-19
4 Laurie A. Miller SVP, Human Resources 40,987 $4.93M -$40.4K 23 2026-06-08
5 Roy Galvin EVP, Chief Commercial Officer 39,805 $4.79M $0 12 2026-11-03
6 Robert E Abernathy Director 27,519 $3.31M $323.7K 11 2026-07-28
7 Mark W Kroll Director 27,295 $3.28M -$7.06M 32 2026-07-28
8 Charles J Dockendorff Director 25,041 $3.01M -$2.53M 13 2025-07-25
9 Ellen M Zane Director 21,911 $2.64M $0 14 2026-07-28
10 Claire Pomeroy Director 19,410 $2.34M $0 9 2026-07-28
Lifetime OM Net = signed sum of open-market buys (P) and sells (S) over their career; excludes grants, tax withholdings, and dispositions to issuer. A large negative number is normal for long-tenured executives — they've sold compensation grants over many years.

HAE Board & Officers

As of SEC filings through Nov 3, 2026

Directors 9

Officers 7

Changes in the last 10 years (25)
Jul 24, 2026Martin D Madaus became a director
Apr 27, 2026The company announced the departure of Charles J Dockendorff from the board in an SEC filing
Jun 13, 2025Roy Galvin listed as EVP, Chief Commercial Officer (previously President, Global Plasma & BC) in SEC filings
Apr 7, 2025Frank Chan became EVP, Chief Operating Officer
Aug 4, 2023Diane M Bryant became a director
Oct 17, 2022Farris Maryanne Maunsell became VP, Chief Accounting Officer
Oct 10, 2022Roy Galvin became President, Global Plasma & BC
Aug 5, 2022The company announced the departure of Dan Goldstein as VP, Corporate Controller in an SEC filing
Apr 11, 2022James DArecca became EVP, Chief Financial Officer
Nov 9, 2021The company announced the departure of William P. Mr. Burke as EVP, Chief Financial Officer in an SEC filing
Sep 9, 2021Josep Llorens listed as EVP, Global Manufacturing (previously SVP, Global Manufacturing) in SEC filings
Aug 30, 2021Laurie A. Miller became SVP, Human Resources
Aug 6, 2021Stewart W Strong became President, Global Hospital
Aug 6, 2021Lloyd Emerson Johnson became a director
Aug 6, 2021Chad M. Nikel became President, Global Plasma & BC
Apr 16, 2020Michael J Coyle became a director
Apr 1, 2020Anila Lingamneni became EVP, Chief Technology Officer
Apr 24, 2019Claire Pomeroy became a director
Aug 20, 2018Josep Llorens became SVP, Global Manufacturing
Jun 8, 2018Christopher Simon first listed as a director in an SEC filing
Not reported recently (13)
  • Stewart W Strong · Last reported as President, Global Hospital in an SEC filing dated Jul 29, 2024
  • Anila Lingamneni · Last reported as EVP, Chief Technology Officer in an SEC filing dated Jul 15, 2024
  • Josep Llorens · Last reported as EVP, Global Manufacturing in an SEC filing dated May 29, 2024
  • Catherine M Burzik · Last reported as a director in an SEC filing dated Aug 8, 2022
  • Chad M. Nikel · Last reported as President, Global Plasma & BC in an SEC filing dated Aug 16, 2021
  • Jacqueline Scanlan · Last reported as SVP, Global Human Resources in an SEC filing dated Jun 9, 2021
  • Richard J Meelia · Last reported as a director in an SEC filing dated Feb 5, 2021
  • Ronald G Gelbman · Last reported as a director in an SEC filing dated Nov 13, 2019
  • Said Bolorforosh · Last reported as EVP, Chief Technology Officer in an SEC filing dated Nov 13, 2019
  • Pedro P Granadillo · Last reported as a director in an SEC filing dated Nov 9, 2018
  • Neil Mr. Ryding · Last reported as EVP, Global Manufacturing in an SEC filing dated Jun 8, 2018
  • Susan Bartlett Foote · Last reported as a director in an SEC filing dated Nov 14, 2017
  • Ronald Merriman · Last reported as a director in an SEC filing dated May 24, 2017
Compiled from SEC filings by the company and its directors and officers. Dates are as stated in those filings. Where no filing says when someone left, we show the last filing that listed them.

HAE Proposed Insider Sales (Form 144)

Latest: 2025-06-26
Last 30d: 0 filings  ·  Last 90d: 0 filings

What is Form 144? A notice of intent to sell restricted or control stock under Rule 144. Affiliates (officers, directors, 10%+ owners) and holders of restricted shares must file Form 144 when planning to sell more than 5,000 shares or $50,000 in any 3-month rolling window.

How it relates to Form 4: Form 144 is filed before the trade (up to 90 days in advance); Form 4 is filed within 2 business days after the trade executes. Not every Form 144 results in a sale — the filer may cancel or delay. Look for the corresponding Form 4 on the Insider Activity card to confirm a sale actually happened.

10b5-1 plans: Trades made under a pre-scheduled Rule 10b5-1 plan are not discretionary — they execute automatically on dates set months earlier, regardless of news. High 10b5-1 percentages mean less per-filing signal value, though cumulative selling volume still matters.

"Notice value": Aggregate market value the filer wrote into the Form 144 — i.e. the size of the planned sale, not necessarily the executed dollars. An amended notice (Form 144/A) replaces the original it amends, and cancelled notices are dropped, so neither is double-counted above. A filed value that is clearly inconsistent with the share count at the stock's price (a filer typo) shows as a dash and is left out of the totals.

Source & freshness: Sourced from public Form 144 filings. Refreshed daily; new filings typically appear here the morning after they are filed.

Filed Filer Role Shares Notice Value Planned Sale Broker Plan Link
2025-06-26 Llorens Josep Former Officer 18,630 $1.40M 2025-06-26 Fidelity Brokerage Services LLC — EDGAR
2025-06-12 Strong Stewart W Former Officer 708 $50.6K 2025-06-12 Fidelity Brokerage Services LLC — EDGAR
2025-06-04 Strong Stewart W Officer 7,705 $538.6K 2025-06-04 Fidelity Brokerage Services LLC 10b5-1 EDGAR
2025-06-02 Strong Stewart W Officer 2,835 $191.3K 2025-06-02 Fidelity Brokerage Services LLC 10b5-1 EDGAR
2025-05-19 Llorens Josep Officer 1,547 $107.3K 2025-05-19 Fidelity Brokerage Services LLC — EDGAR
2024-11-12 Lingamneni Anila Former Officer 6,238 $565.7K 2024-11-11 Fidelity Brokerage Services LLC — EDGAR
2024-07-26 Strong Stewart W Officer 4,312 $393.0K 2024-07-26 Fidelity Brokerage Services LLC 10b5-1 EDGAR
2024-07-12 Lingamneni Anila Officer 79 $7.1K 2024-07-12 Fidelity Brokerage Services LLC 10b5-1 EDGAR
2024-07-11 Lingamneni Anila Officer 2,136 $192.2K 2024-07-11 Fidelity Brokerage Services LLC 10b5-1 EDGAR
2024-05-29 Basil Michelle L Officer 12,990 $1.14M 2024-05-29 Fidelity Brokerage Services LLC 10b5-1 EDGAR
Notice value is the aggregate market value the filer states they intend to sell — not a confirmed transaction. Compare to Insider Activity (Form 4) to see which planned sales actually executed. Market-wide feed: Planned sales (Form 144).
Recent SEC Filings
Latest: 2026-11-05
Current reports — material events the company must disclose within 4 business days (earnings releases, M&A, executive changes, etc.).
Filing Date Event Link
2026-11-05 Earnings results EDGAR
2026-10-08 Regulation FD disclosure EDGAR
2026-08-18 Regulation FD disclosure EDGAR
2026-08-06 Earnings results EDGAR
2026-07-28 Director or officer change · Shareholder vote results EDGAR
2026-06-05 Regulation FD disclosure EDGAR
2026-05-07 Earnings results EDGAR
2026-05-01 Director or officer change EDGAR
2026-03-03 Regulation FD disclosure EDGAR
2026-02-12 Regulation FD disclosure EDGAR
Annual report — audited financial statements, MD&A, risk factors. Filed 60–90 days after fiscal year-end.
Filing Date Accession Link
2026-05-20 0000313143-26-000050 EDGAR
2025-05-21 0000313143-25-000025 EDGAR
2024-05-20 0000313143-24-000020 EDGAR
2023-05-22 0000313143-23-000014 EDGAR
2022-05-25 0000313143-22-000024 EDGAR
2021-05-26 0000313143-21-000023 EDGAR
2020-05-20 0000313143-20-000028 EDGAR
2019-05-22 0000313143-19-000022 EDGAR
2018-05-23 0000313143-18-000020 EDGAR
2017-05-24 0000313143-17-000017 EDGAR
Quarterly report — unaudited financials and MD&A. Filed 40–45 days after each of the first three fiscal quarters.
Filing Date Accession Link
2026-11-05 0000313143-26-000152 EDGAR
2026-08-06 0000313143-26-000120 EDGAR
2026-02-05 0000313143-26-000010 EDGAR
2025-11-06 0000313143-25-000075 EDGAR
2025-08-07 0000313143-25-000058 EDGAR
2025-02-06 0000313143-25-000012 EDGAR
2024-11-07 0000313143-24-000063 EDGAR
2024-08-08 0000313143-24-000054 EDGAR
2024-02-08 0000313143-24-000007 EDGAR
2023-11-02 0000313143-23-000057 EDGAR
ETF Holders
121 ETFs hold HAE
25 shown · $1.10B total exposure · 0.18% AUM-weighted avg weight
# ETF Provider Weight $ Exposure ETF AUM As Of
1 IJH iShares Core S&P Mid-Cap ETF iShares (BlackRock) 0.16% $197.4M $121.4B 2026-11-06
2 VTI Vanguard Morningstar Total Stock Market ETF Vanguard 0.01% $152.6M — 2026-09-30
3 IWM iShares Russell 2000 ETF iShares (BlackRock) 0.19% $143.6M $76.6B 2026-11-06
4 VB Vanguard Morningstar Small-Cap ETF Vanguard 0.06% $107.9M — 2026-09-30
5 VXF Vanguard Extended Market ETF Vanguard 0.06% $54.0M — 2026-09-30
6 IWO iShares Russell 2000 Growth ETF iShares (BlackRock) 0.36% $49.3M $13.7B 2026-11-06
7 DFAS Dimensional US Small Cap ETF Dimensional 0.13% $43.8M — 2026-11-05
8 MDY State Street® SPDR® S&P MIDCAP 400® ETF Trust SPDR (State Street) 0.17% $43.1M $25.6B 2026-11-05
9 VBR Vanguard Morningstar Small-Cap Value ETF Vanguard 0.05% $35.1M — 2026-09-30
10 SPMD State Street® SPDR® Portfolio S&P 400™ Mid Cap ETF SPDR (State Street) 0.17% $31.0M $18.3B 2026-11-05
11 VBK Vanguard Morningstar Small-Cap Growth ETF Vanguard 0.07% $30.0M — 2026-09-30
12 VTWO Vanguard Russell 2000 ETF Vanguard 0.16% $28.2M — 2026-09-30
13 DFAC Dimensional US Core Equity 2 ETF Dimensional 0.03% $22.9M — 2026-11-05
14 SCHA Schwab U.S. Small-Cap ETF Nport 0.10% $22.8M — 2026-08-31
15 IJK iShares S&P Mid-Cap 400 Growth ETF iShares (BlackRock) 0.20% $20.0M $10.2B 2026-11-06
16 DFMC Dimensional US Micro Cap ETF Dimensional 0.26% $19.5M — 2026-11-05
17 FNDA Schwab Fundamental U.S. Small Company ETF Nport 0.17% $15.6M — 2026-08-31
18 VHT Vanguard Health Care ETF Vanguard 0.07% $14.6M — 2026-09-30
19 AVSC Avantis U.S. Small Cap Equity ETF Avantis 0.35% $11.2M $3.2B 2026-11-05
20 IJJ iShares S&P Mid-Cap 400 Value ETF iShares (BlackRock) 0.13% $11.2M $8.6B 2026-11-06
21 DCOR Dimensional US Core Equity 1 ETF Dimensional 0.02% $9.8M — 2026-11-05
22 FESM Fidelity Enhanced Small Cap Core ETF Fidelity 0.14% $9.6M $6.6B 2026-11-05
23 JMEE JPMorgan Small & Mid Cap Enhanced Equity ETF JPMorgan 0.31% $8.8M $2.9B 2026-11-06
24 PSC Principal U.S. Small-Cap ETF Nport 0.35% $8.3M — 2026-06-30
25 IVOO Vanguard S&P Mid-Cap 400 ETF Vanguard 0.14% $8.0M — 2026-09-30
Fundamentals

Quarterly filings sourced from SEC 10-Q / 10-K reports. TTM tiles aggregate the most recent four quarters; bars show the last ~12 quarters oldest → newest.

Metrics
  • Revenue — top-line sales. Look for consistent YoY growth; seasonal businesses need same-quarter comparisons (Q4 '24 vs Q4 '23).
  • Net Income — bottom-line profit after all expenses. Can be volatile from one-time items; red bars = net loss.
  • Diluted EPS — net income per share assuming options/converts are exercised. Direct input to the P/E ratio.
  • Operating Cash Flow — cash generated from core operations, before capex and financing. Harder to manipulate than net income; growing OCF is a quality signal.
How to read the bars
  • Sequential growth — quarter-over-quarter trend. Accelerating bars are a momentum signal.
  • YoY growth — compare to the same quarter a year earlier to remove seasonality.
  • Quality — OCF should roughly track Net Income over time. Large divergence (net income ≫ OCF) flags accruals risk.
  • Margins — scan the bar ratios: Net Income / Revenue tells you margin trend without needing a separate chart.

TTM (trailing-twelve-month) smooths seasonality and is used for the P/E calculation. Filings appear 30–90 days after the period closes.

Trailing P/E
58.43
TTM Diluted EPS
$2.05
TTM Revenue
$1.33B
TTM Net Income
$97.31M
TTM Op. Cash Flow
$293.22M
Quarterly figures (12 quarters)
QuarterPeriod EndRevenueNet IncomeDiluted EPSOp. Cash Flow
Q4 '262026-03-28$346.35M$-20.15M$-0.41$70.94M
Q3 '262025-12-27$338.97M$44.74M$0.95$93.56M
Q2 '262025-09-27$327.31M$38.68M$0.81$111.32M
Q1 '262025-06-28$321.39M$34.03M$0.70$17.39M
Q4 '252025-03-29$330.60M$57.98M$1.17$116.56M
Q3 '252024-12-28$348.54M$37.49M$0.74$43.77M
Q2 '252024-09-28$345.51M$33.83M$0.66$48.82M
Q1 '252024-06-29$336.17M$38.37M$0.74$-27.42M
Q4 '242024-03-30$343.29M$20.37M$0.40$64.08M
Q3 '242023-12-30$336.25M$31.24M$0.61$-3.41M
Q2 '242023-09-30$318.18M$24.91M$0.48$102.00M
Q1 '242023-07-01$311.33M$41.04M$0.80$19.09M
Q4 2026 • period ending 2026-03-28 • filed 2026-05-20
Valuation

Ratios derived from TTM financials and the current market price, sampled daily. History chart shows how expensive the stock is today relative to its own recent past.

Price Multiples
  • P/E — price / TTM earnings. Rough market rule: 10–15 value, 15–25 market, >30 growth/premium. Negative when earnings are negative.
  • P/B — price / book value. Useful for financials and asset-heavy names; meaningless for asset-light software.
  • P/S — price / TTM revenue. Useful when earnings are negative or noisy (early-stage growth).
  • EV/EBITDA — capital-structure-neutral. <10 cheap, 10–15 reasonable, >20 rich. Good for comparing across leverage profiles.
  • EV/Sales — like P/S but accounts for debt + cash. Compare within sector.
Profitability & Yields
  • ROE — return on equity. >15% strong, >25% exceptional. Caution: high leverage inflates ROE.
  • ROA — return on assets. Leverage-neutral; >5% solid, >10% exceptional.
  • Div Yield — annual dividend / price. Compare to 10Y Treasury; sustained yield >6% often signals distress.
  • FCF Yield — free cash flow / market cap. >5% is attractive; negative means burning cash.
Balance Sheet
  • Debt/Equity — leverage. <1 conservative, >2 aggressive. Sector-dependent (utilities naturally high, tech low).
  • Current Ratio — short-term liquidity. >1.5 comfortable, <1 raises short-term solvency flags.
Reading the history chart
  • Compare current level to the 3-year band: near the high end = relatively expensive; near the low = relatively cheap.
  • Multiples expanding while earnings are flat = sentiment-driven rally.
  • Multiples compressing while earnings grow = value coming from fundamentals.
P/E
58.43
P/B
7.16
P/S
4.27
EV/EBITDA
18.80
EV/Sales
5.00
ROE
12.2%
ROA
4.1%
Div Yield
0.00%
FCF Yield
5.14%
Debt/Equity
1.53
Current Ratio
—
Market Cap
$5.70B
as of 2026-11-09

HAE vs Peers

Related companies, largest first
Company Market cap P/E Revenue growth YTD IV rank
GEHC GE HealthCare Technologies Inc. Common S $37.2B 17.8 +6.9% +2.0% 30
GKOS Glaukos Corporation $13.3B — +46.9% +113.1% 25
PODD Insulet Corporation $10.2B 28.1 +29.4% −47.0% 33
HAE Haemonetics Corporation $5.5B 58.7 −2.0% +50.5% 3
MMSI Merit Medical Systems Inc $5.2B 33.5 +9.1% +3.2% 23
NVST Envista Holdings Corporation Common stoc $4.0B 45.4 +11.9% +21.5% 47
NEOG Neogen Corp $2.6B — −0.3% +73.9% 8
UFPT UFP Technologies Inc $2.4B 35.2 +7.3% +45.8% 44
ENOV Enovis Corporation $1.6B — +4.9% +6.5% 41
Peer median $4.6B 33.5 +8.2% +14.0% 32

P/E uses the latest reported trailing-12-month diluted EPS; "—" means no positive earnings or no data.

Short Interest & Float

Regulatory short-interest reports publish on a bi-weekly settlement cadence; short-volume is reported daily by the trade-reporting facilities. Float is derived from insider-ownership filings.

Metric definitions
  • Short Interest — total shares currently sold short as of the settlement date. Lags real time by ~8 business days.
  • SI % of Float — short interest / free float. The key crowding metric.
  • Days to Cover — short interest / avg daily volume. How many full trading days it would take shorts to buy back. High DTC + catalyst = squeeze fuel.
  • Short Vol Ratio — today's short-sale volume / total volume. Intraday selling pressure proxy (not the same as short interest).
  • Free Float — shares available for public trading (total shares minus insider / restricted).
  • Float % — free float / shares outstanding. <50% = tightly held, more prone to squeezes.
How to read the signals
  • SI % of Float < 5% — typical, no particular signal.
  • 5–15% — elevated; watch for catalysts (earnings, guidance, macro).
  • 15–30% — heavily shorted; tight-float names in this range have produced notable squeezes historically.
  • >30% — extreme; borrow is likely expensive and squeeze risk is material.
  • Days to Cover > 5 combined with high SI% amplifies squeeze potential.
History chart
  • Trend matters more than level. Rapidly rising short interest often precedes negative catalysts or heavy hedging.
  • A sudden drop in SI after a rally may indicate a squeeze in progress.

Short interest is reported mid-month and end-of-month; short volume is daily.

Short Interest
3.43M
SI % of Float
7.70%
Days to Cover
3.89
Short Vol Ratio
54.8%
Free Float
44.52M
Float %
97.9%
Short interest 2026-10-15 • Short volume 2026-11-06 • Float 2026-08-24